RecruitingNCT06207032
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Sponsor
Tempus AI
Enrollment
500 participants
Start Date
Jun 26, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Eligibility
Min Age: 18 YearsMax Age: 99 Years
Inclusion Criteria4
- ≥18 years of age
- Willing to participate in the research
- Able to provide informed consent
- Must be diagnosed with cancer
Exclusion Criteria1
- \. Not willing or able to have additional blood samples collected
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(32)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06207032
Related Trials
Immunotherapy Treating GI Cancer
NCT036146501 location
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
Tumor Related Epilepsy
NCT026393251 location
Cancer-related Venous Thromboembolic Disease - Cohort Study
NCT063937641 location
Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy
NCT073541001 location